← Leaderboards
Paul Sebahar
Curza Inc
$2,858,436
Attributed
$2,858,436
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2023–25$1M$750K$500K$250K$0
'23
'24
'25
Funding mix
By agency
NIH$2,858,436 · 1
By mechanism
R44$2,858,436 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Acinetobacter Baumannii”
- Justin Blaine Schaal · University Of Southern California$3,025,760
- Tsuyoshi Uehara · Venatorx Pharmaceuticals, Inc.$2,000,000
- Yanan Zhao · State University Of New York At Buffalo$1,596,741
- Despoina Mavridou · University Of Texas At Austin$1,558,092
- Vidmantas Petraitis · Hackensack University Medical Center$1,428,749
- Yinzhi Lang · University Of Florida$1,261,878
Research focus
Acinetobacter BaumanniiAcute ToxicityAnalogAnimal ModelAnti-Bacterial AgentsAntibioticsAutopsyBacteremiaBacteriaBacterial Antibiotic ResistanceBacterial Drug ResistanceBacterial ProteinsBindingBinding ProteinsBiochemicalBiologicalBloodBody WeightCandidate SelectionCarbapenem ResistanceCellsChemistryClinical ChemistryAbdominal Infection
Grant awards (3)
A New Class of Broad-Spectrum Antibacterial Agents to Treat Multi-Drug Resistant Pathogens$858,436
R44 · FY2025 · AI · contact PI
A New Class of Broad-Spectrum Antibacterial Agents to Treat Multi-Drug Resistant Pathogens$1,000,000
R44 · FY2024 · AI · contact PI
A New Class of Broad-Spectrum Antibacterial Agents to Treat Multi-Drug Resistant Pathogens$1,000,000
R44 · FY2023 · AI · contact PI